What is the recommended first‑line therapy for uncomplicated genital Chlamydia trachomatis infection, including options for pregnancy, doxycycline allergy, partner management, and co‑existing Neisseria gonorrhoeae?

Treatment for Chlamydia

Doxycycline 100 mg orally twice daily for 7 days is the recommended first-line therapy for uncomplicated genital chlamydia in non-pregnant adults, achieving 98% cure rates. 1

First-Line Treatment Options

Both doxycycline and azithromycin are equally effective first-line agents, but the choice depends on specific clinical circumstances:

Doxycycline 100 mg orally twice daily for 7 days

• Achieves 98% cure rate for uncomplicated genital chlamydia 2, 1
• Superior efficacy for rectal chlamydia (94-100% cure vs. 79-87% with azithromycin) 1
• Lower cost than azithromycin with extensive clinical experience 2, 1
• Preferred when compliance is reliable and cost is a concern 1, 3
• Once-daily alternative: Doxycycline delayed-release 200 mg once daily for 7 days achieves 95.5% cure with better tolerability (13% nausea vs. 21% with standard dosing) 1

Azithromycin 1 g orally as a single dose

• Achieves 97% cure rate for uncomplicated genital chlamydia 2, 1
• Preferred when compliance is uncertain because it enables directly observed therapy 2, 1, 3
• Better for populations with erratic health-care-seeking behavior (e.g., homeless individuals, adolescents) 2, 1
• Should be dispensed on-site with first dose directly observed to maximize compliance 2, 1

Treatment During Pregnancy

Azithromycin 1 g orally as a single dose is the preferred treatment for pregnant women. 2, 1

Pregnancy-Safe Options

• First-line: Azithromycin 1 g orally, single dose 2, 1
• Alternative: Amoxicillin 500 mg orally three times daily for 7 days 2, 1
• Secondary alternatives (if above cannot be used):
  • Erythromycin base 500 mg orally four times daily for 7 days 1
  • Erythromycin ethylsuccinate 800 mg orally four times daily for 7 days 1

Absolute Contraindications in Pregnancy

• Doxycycline (teratogenic risk) 2, 1
• All fluoroquinolones (ofloxacin, levofloxacin) 2, 1
• Erythromycin estolate (drug-related hepatotoxicity) 1

Mandatory Follow-Up in Pregnancy

• Test-of-cure is mandatory 3-4 weeks after completing therapy (unlike non-pregnant patients) 1
• Culture is preferred when available; if using NAAT, wait ≥3 weeks to avoid false-positives 1

Alternative Regimens (Doxycycline Allergy or Intolerance)

When first-line agents cannot be used:

• Erythromycin base 500 mg orally four times daily for 7 days 2, 1
• Erythromycin ethylsuccinate 800 mg orally four times daily for 7 days 2, 1
• Ofloxacin 300 mg orally twice daily for 7 days 2, 1
• Levofloxacin 500 mg orally once daily for 7 days (88-94% efficacy vs. 97-98% for first-line agents; lacks clinical trial validation) 2, 1

Important caveat: Erythromycin has poor compliance due to gastrointestinal side effects and should not be used as first-line 2, 1

Partner Management Protocol

All sex partners from the previous 60 days must be evaluated, tested, and empirically treated immediately—do not wait for test results. 2, 1, 3

Partner Treatment Algorithm

1. Treat partners empirically before their test results are available (failure to do so leads to reinfection in up to 20% of cases) 2, 1, 3
2. If last sexual contact was >60 days before diagnosis, treat the most recent partner 2, 1, 3
3. Use the same regimen as the index patient (azithromycin or doxycycline) 1
4. Partners should abstain from sex for 7 days after starting treatment and until all partners complete therapy 2, 1, 3

Co-Existing Gonorrhea Management

If gonorrhea is confirmed or prevalence exceeds 5% in your population, treat both infections concurrently. 2, 1, 3

Dual Therapy Regimen

• Ceftriaxone 500 mg IM single dose PLUS azithromycin 1 g orally single dose 2, 1, 3
• Rationale: Coinfection rates range from 20-40% in many populations 2, 1, 3
• Test for gonorrhea at initial visit using NAAT 1, 3

Sexual Activity Restrictions

Patients must abstain from all sexual intercourse for 7 days after initiating treatment, regardless of regimen. 2, 1, 3

• Abstinence continues until all sex partners have completed treatment 2, 1, 3
• This applies to single-dose azithromycin and 7-day doxycycline equally 1, 3

Follow-Up and Retesting

Test-of-Cure (NOT Routinely Recommended)

• Do NOT perform test-of-cure in non-pregnant patients treated with recommended regimens who are asymptomatic (cure rates exceed 97%) 2, 1, 3
• Only perform test-of-cure if:
  • Therapeutic compliance is questionable 2, 1
  • Symptoms persist after treatment 2, 1
  • Reinfection is suspected 2, 1
  • Patient is pregnant (mandatory) 1
• Do NOT test before 3 weeks post-treatment (NAAT can yield false-positives from dead organisms) 1

Reinfection Screening (Mandatory)

• All women must be retested at 3 months after treatment to screen for reinfection 2, 1, 3
• Reinfection rates reach up to 39% in some populations 1
• Repeat infections carry elevated risk for pelvic inflammatory disease compared to initial infection 2, 1, 3

Additional STI Testing at Initial Visit

Test for gonorrhea, syphilis, and HIV at the time of chlamydia diagnosis. 1, 3

• Gonorrhea NAAT (coinfection rates 20-40%) 1, 3
• Syphilis serology 1
• HIV testing 1
• Consider HPV vaccination referral if age-appropriate 1

Pediatric Dosing

Children ≥8 years weighing >45 kg

• Azithromycin 1 g orally, single dose OR doxycycline 100 mg orally twice daily for 7 days 2, 1

Children <45 kg

• Erythromycin base or ethylsuccinate 50 mg/kg/day orally divided into four doses for 14 days 2, 1

Neonates with chlamydial conjunctivitis or pneumonia (1-3 months)

• Erythromycin base or ethylsuccinate 50 mg/kg/day orally divided into four doses for 14 days (80% effective; may need second course) 2, 1

Common Pitfalls to Avoid

• Do NOT wait for test results in high-prevalence populations or when compliance is uncertain—treat presumptively 1, 3
• Do NOT assume partners were treated—directly verify or use expedited partner therapy 1, 3
• Do NOT perform test-of-cure before 3 weeks (false-positives from dead organisms) 1
• Do NOT use erythromycin as first-line (poor compliance from GI side effects) 2, 1
• Do NOT use doxycycline, fluoroquinolones, or erythromycin estolate in pregnancy 2, 1
• Do NOT omit the mandatory 3-month reinfection screening in women 2, 1, 3